⌘K
Loading ticker…
As of 2026-08-24, Cullinan Therapeutics, Inc. Common Stock (CGEM) has a 3-month relative strength percentile of 95 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 80. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.4%, relative volume 0.89×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CGEM is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 21.6% / 56.1%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CGEM is held by 25 ETFs as of May 2026. Top owner: VTWO at 0.03% weight, $5M notional. Top 3 carry $11M.
Held by 49 ETFs · $112M across latest filings · largest weight 0.81% (BBC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.01% |
| $1M |
| — |
| CANC | 0.59% | $1M | +0.13 pp |
| VTWV | 0.05% | $698K | — |
| ONEQ | 0.01% | $610K | new |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $499K | — |
Showing 10 of 25 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CGEM Jan avg: 15.29% median: 12.94% win: 75% σ: 25.50% n: 4 2022-04-12 → 2026-07-31 | CGEM Feb avg: 7.25% median: 9.49% win: 50% σ: 22.68% n: 4 2022-04-12 → 2026-07-31 | CGEM Mar avg: -9.07% median: -8.86% win: 0% σ: 1.36% n: 4 2022-04-12 → 2026-07-31 | CGEM Apr avg: 8.67% median: -4.89% win: 40% σ: 28.97% n: 5 2022-04-12 → 2026-07-31 | CGEM May avg: 6.40% median: 5.65% win: 80% σ: 13.88% n: 5 2022-04-12 → 2026-07-31 | CGEM Jun avg: -0.66% median: 4.67% win: 60% σ: 18.46% n: 5 2022-04-12 → 2026-07-31 | CGEM Jul avg: 1.71% median: 3.19% win: 60% σ: 7.67% n: 5 2022-04-12 → 2026-07-31 | CGEM Aug avg: -1.04% median: -1.24% win: 25% σ: 1.94% n: 4 2022-04-12 → 2026-07-31 (current) | CGEM Sep avg: -13.35% median: -13.58% win: 0% σ: 6.77% n: 4 2022-04-12 → 2026-07-31 | CGEM Oct avg: 11.13% median: 2.79% win: 75% σ: 23.74% n: 4 2022-04-12 → 2026-07-31 | CGEM Nov avg: 0.04% median: -8.81% win: 25% σ: 21.14% n: 4 2022-04-12 → 2026-07-31 | CGEM Dec avg: -2.28% median: -9.21% win: 25% σ: 18.02% n: 4 2022-04-12 → 2026-07-31 |